Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses

Journal of Prevention of Alzheimer's Disease · Published 2026-05-27 · DOI 10.1016/j.tjpad.2026.100605

Free full text

Authors (13)

Frank Jessen, Grazia Dell’Agnello, Jennifer A. Zimmer, Christophe Sapin, Sascha Dichter, Erin Doty, Stéphane Epelbaum, Cynthia D. Evans, Paula M. Hauck, Rashna Khanna, Dawn A. Brooks, John R. Sims, Federica Agosta

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Jessen, F., Dell’Agnello, G., Zimmer, J., et al. (2026). Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses. Journal of Prevention of Alzheimer's Disease. https://doi.org/10.1016/j.tjpad.2026.100605

Related articles

• Reductions in neuropsychiatric symptoms after lecanemab treatment and their associations with imaging markers of β-amyloid clearance · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Combined effect of anxiety disorder and insomnia on the risk of incident ADRD diagnosis · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Sex differences in subjective cognition among middle-aged and older Hispanic/Latino adults: Findings from the HCHS/SOL and SOL-INCA · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Plasma brain-derived p-Tau217 outperforms other p-Tau species in detecting abnormal brain amyloid in an Asian cohort of older people with cerebrovascular disease burden · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Suboptimal adherence to brain health recommendations in patients pursuing anti-amyloid antibody therapy for Alzheimer’s disease: Report from the Brain Health Vital Signs project · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Depressive symptoms as a risk factor or prodrome of dementia: multi-state cognitive transitions modified by age and polygenic risk · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Tailored implementation of multidomain intervention to prevent cognitive impairment in community-dwelling older adults (Timi-Cog): A study protocol for a hybrid type 2 trial effectiveness-implementation study · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Top five Alzheimer Disease trial eligibility criteria favor men compared to women in a clinic-based cohort · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Associations of plasma biomarkers with age in the presenilin-1 E280A autosomal dominant Alzheimer's disease kindred · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal
• Eligibility of men vs. women in Alzheimer’s trials: Inclusive vs. representative · Journal of Prevention of Alzheimer's Disease · 2026 · Same journal